Gliclazide increases glucose utilization by rat intestine in vitro

Area of Science:

• Endocrinology
• Gastroenterology
• Pharmacology

Background:

• Glucose metabolism and absorption are critical physiological processes.
• Sulfonylureas, like gliclazide, are commonly used hypoglycemic agents.
• Understanding drug effects on intestinal glucose handling is vital for metabolic research.

Purpose of the Study:

• To investigate the effects of gliclazide on glucose absorption and utilization.
• To assess gliclazide's impact on lactate production in the intestine-pancreas.
• To determine if gliclazide alters glucose translocation from the lumen to the blood.

Main Methods:

• Utilized an in vitro perfused rat intestine-pancreas preparation.
• Administered glucose intraluminally and arterially.
• Tested gliclazide at a concentration of 200 micrograms/ml.
• Measured glucose utilization and lactate production at varying arterial glucose concentrations.

Main Results:

• Gliclazide significantly increased intestinal glucose utilization at all tested arterial glucose concentrations (2.75, 5.5, 11.0 mmol/l).
• Lactate production remained unchanged in the presence of gliclazide.
• Gliclazide reduced glucose translocation from the lumen to the blood without affecting the overall intestinal absorption rate.

Conclusions:

• Gliclazide (200 micrograms/ml) enhances the metabolic utilization of glucose supplied via arterial or intraluminal routes.
• The drug improves glucose metabolism in the isolated perfused rat intestine-pancreas.
• Gliclazide's effects on glucose translocation and utilization warrant further investigation in metabolic studies.